angiotensin
convert
enzym
monocarboxypeptidas
metabol
sever
peptid
includ
degrad
ang
ii
peptid
vasoconstrictiveproliferativeeffect
gener
ang
act
receptor
ma
exert
vasodilatoryantiprolif
action
classic
pathway
ra
involv
aceang
iiat
receptor
axi
antagon
second
arm
constitut
receptor
axi
loss
enhanc
advers
patholog
remodel
suscept
pressureoverload
myocardi
infarct
human
recombin
also
neg
regul
ang
iiinduc
myocardi
hypertrophi
fibrosi
diastol
dysfunct
suppress
pressureoverload
induc
heart
failur
due
characterist
axi
may
repres
new
possibl
develop
novel
therapeut
strategi
treatment
heart
failur
human
recombin
safe
administ
healthi
human
volunt
intraven
result
sustain
lower
plasma
ang
ii
level
review
summar
benefici
effect
heart
diseas
potenti
use
human
recombin
novel
therapi
heart
failur
reninangiotensin
system
ra
peptiderg
system
endocrin
characterist
function
homeostat
control
arteri
pressur
tissu
perfus
extracellular
volum
central
regul
cardiovascular
renal
function
play
key
role
pathophysiolog
variou
cardiovascular
disord
ra
consist
seri
enzymat
reaction
culmin
gener
angiotensin
ii
ang
ii
first
step
enzymat
reaction
renin
aspartyl
proteas
secret
kidney
circul
cleav
hepat
peptid
angiotensinogen
produc
angiotensin
ang
blood
second
step
involv
hydrolysi
ang
angiotensinconvert
enzym
ace
result
product
bioactiv
octapeptid
ang
ii
promot
vasoconstrict
inflamm
salt
water
reabsorpt
oxid
stress
classic
ra
famili
seen
substanti
conceptu
chang
identif
angiotensinconvert
enzym
neg
regul
ra
angiotensinconvert
enzym
homologu
ace
discov
function
import
enzym
becom
unequivoc
initi
identifi
human
heart
failur
lymphoma
cdna
librari
later
shown
serv
receptor
sar
coronaviru
ace
transmembran
enzym
homolog
share
ident
cytosol
sheddas
transmembran
noncatalyt
extracellular
domain
though
nonsensit
acei
contrast
ace
dipeptidyl
carboxypeptidas
monocarboxypeptidas
degrad
ang
gener
ang
ang
ii
gener
heptapeptid
ang
biolog
activ
metabolit
ang
act
membran
bound
ma
receptor
masr
whose
action
often
opposit
attribut
ang
ii
ang
masr
axi
shown
counteract
variou
pathway
trigger
ang
iiat
r
axi
activ
pathway
includ
classic
hypertroph
pathway
mapk
protein
kinas
c
pkc
fig
ang
iiat
r
axi
activ
suppress
pathway
wherea
ang
masr
axi
stimul
pathway
lead
increas
cell
surviv
thu
aceang
ii
r
wellestablish
axi
ra
masr
axi
provid
physiolog
antagon
result
counterregul
ra
fig
suggest
effect
mediat
could
attribut
suppress
ang
iiat
r
axi
activ
andor
stimul
ang
masr
axi
activ
understand
rel
import
axe
studi
pressur
overload
model
null
mice
treat
irbesartan
ang
found
function
redund
cardioprotect
effect
irbesartan
well
ang
shown
suppress
nadph
oxidas
activ
activ
patholog
signal
suggest
equival
import
axe
howev
cardiac
plasma
ra
peptid
level
assess
nonfail
control
patient
heart
failur
requir
categor
patient
therapeut
categori
tailor
therapi
human
heart
failur
interestingli
anoth
import
product
mediat
ang
degrad
ang
recent
shown
promis
cardioprotect
effect
anim
model
hypertens
myocardi
infarct
ang
supplement
spontan
hypertens
rat
shr
affect
blood
pressur
cardiac
function
left
ventricular
mass
index
howev
ang
significantli
reduc
cardiac
fibrosi
effect
found
mediat
via
r
activ
induc
increas
bioavail
floresmunoz
et
al
studi
effect
adenovir
deliveri
ang
well
ang
rat
cardiomyocyt
found
compar
antihypertroph
effect
recent
rhoarhokinas
inhibit
signal
pathway
particip
patholog
cardiovascular
renal
remodel
also
blood
pressur
regul
reduc
blood
pressur
increas
vascular
plasma
activ
along
reduc
ang
ii
increas
ang
plasma
level
conclud
antihypertens
effect
rhoarhokinas
inhibit
might
mediat
via
r
axi
rhoa
rhokinas
inhibit
result
chang
ang
level
review
mainli
focu
role
manipul
ang
ii
metabol
enhanc
action
potenti
therapeut
regimen
heart
failur
biomark
heart
failur
along
member
system
ra
also
wide
distribut
local
ra
exist
cardiovascular
tissu
mrna
present
variou
celltyp
includ
coronari
microcircul
cardiofibroblast
cardiomyocyt
play
critic
role
control
cardiac
physiolog
alter
express
link
major
pathophysiolog
chang
cardiovascular
system
fig
human
popul
genet
variabl
gene
correl
suscept
cardiovascular
diseas
singl
nucleotid
polymorph
snp
associ
variat
left
ventricular
mass
septal
wall
thick
ventricular
hypertrophi
coronari
heart
diseas
myocardi
infarct
hypertens
patient
metabol
syndrom
fail
human
heart
ventricl
increas
ang
form
activ
may
reflect
increas
activ
gene
express
increas
dilat
ischem
cardiomyopathi
genet
target
experi
indic
import
regul
cardiac
function
first
evid
show
endogen
cardiac
regul
shown
knockout
mice
delet
gene
result
abnorm
heart
function
loss
result
worsen
patholog
remodel
associ
systol
dysfunct
ventricular
dilat
respons
pressur
overload
induc
biomechan
stress
due
trigger
activ
myocardi
napdh
oxidas
system
superoxid
product
activ
matrix
metalloproteinas
benefici
effect
human
recombin
also
demonstr
clinic
relev
model
pressureoverload
induc
heart
failur
interestingli
myocardi
protein
level
found
reduc
substanti
wildtyp
mice
subject
pressur
overload
therebi
perpetu
patholog
effect
ang
ii
suggest
invers
relationship
myocardi
protein
level
diseas
progress
recent
studi
role
prevent
progress
diabet
cardiomyopathi
use
akita
diabet
model
develop
doubl
mutant
mice
studi
month
age
loss
result
systol
dysfunct
background
impair
diastol
function
akita
heart
akita
doubl
mutant
heart
show
increas
nadph
oxidas
activ
result
increas
ro
protein
kinas
c
matrix
metalloproteinas
activ
enhanc
cardiac
extracellular
matrix
degrad
lead
progress
diabet
cardiomyopathi
systol
dysfunct
role
ischem
cardiomyopathi
also
unveil
use
ladlig
model
show
mice
increas
mortal
worsen
heart
function
follow
myocardi
infarct
myocardi
level
ang
ii
ang
increas
decreas
respect
result
greater
inflamm
nadph
oxidas
activ
degrad
extracellular
matrix
consist
result
overexpress
amelior
left
ventricular
remodel
dysfunct
rat
model
myocardi
infarct
diastol
heart
failur
diastol
dysfunct
defin
american
heart
associ
heart
failur
preserv
eject
fraction
hfpef
often
associ
normal
small
heart
size
diastol
fill
abnorm
recent
accept
prognosi
individu
diastol
dysfunct
associ
pulmonari
edema
better
systol
dysfunct
recent
epidemiolog
studi
heart
failur
demonstr
hfpef
account
approxim
heart
failur
similar
mortal
rate
patient
systol
heart
failur
studi
role
clinic
relev
anim
model
ang
ii
infus
mice
result
increas
plasma
myocardi
ang
ii
level
neg
regul
pathophysiolog
effect
pressor
subpressor
dose
wwwdrugdiscoverytodaycom
ang
ii
myocardi
structur
function
loss
result
worsen
cardiac
fibrosi
patholog
hypertrophi
result
worsen
diastol
dysfunct
respons
ang
ii
infus
howev
increas
action
use
lower
plasma
myocardi
ang
ii
level
increas
plasma
ang
level
vivo
provid
definit
evid
key
role
metabol
ang
ii
pharmacolog
treatment
attenu
myocardi
fibrosi
patholog
hypertrophi
diastol
dysfunct
seen
respons
ang
ii
infus
cardiac
fibroblast
express
receptor
ma
receptor
ang
ii
known
induc
product
collagen
larg
inhibit
thu
treatment
antagon
activ
ra
via
switch
biochem
milieu
aceang
iiat
r
arm
ang
masr
arm
importantli
alter
baselin
plasma
ang
ii
ang
blood
pressur
wt
mice
suggest
substrat
avail
limit
factor
enzymat
activ
human
recombin
treatment
also
inhibit
effect
ang
ii
murin
adult
ventricular
cardiomyocyt
cardiac
fibroblast
via
ang
masr
depend
manner
addit
lentivir
transfect
cultur
fibroblast
show
decreas
product
collagen
respons
acut
hypox
exposur
consist
result
overexpress
protect
heart
myocardi
injuri
induc
ang
ii
infus
rat
propos
essenti
neg
regul
ra
depend
diastol
heart
failur
predominantli
set
increas
ang
ii
level
import
ra
develop
progress
kidney
diseas
well
establish
short
term
activ
ra
vital
maintain
renal
homeostasi
occur
expens
glomerular
hypertens
along
import
ra
compon
also
present
kidney
member
local
renal
ra
highli
express
mous
kidney
activ
higher
mous
kidney
cortex
mous
heart
tissu
role
renal
ra
renal
well
studi
use
variou
anim
model
loss
exacerb
ang
ii
induc
renal
oxid
stress
inflamm
fibrosi
treatment
prevent
patholog
chang
fig
consist
result
fang
et
al
use
murin
model
renal
ischemiareperfus
injuri
shown
loss
exacerb
renal
inflamm
oxid
stress
apoptosi
respons
acut
kidney
injuri
diabet
nephropathi
one
common
caus
endstag
renal
failur
found
loss
acceler
diabet
kidney
injuri
reduc
progress
diabet
nephropathi
patient
kidney
dysfunct
higher
risk
advers
cardiovascular
outcom
frequent
develop
left
ventricular
hypertrophi
burchil
et
al
studi
role
kidney
injuri
induc
cardiac
remodel
use
rat
model
acut
kidney
injuri
found
acut
kidney
injuri
led
advers
cardiac
remodel
increas
cardiac
gene
express
activ
thought
compensatori
respons
howev
studi
requir
explain
role
possibl
crosstalk
renal
cardiac
kidney
dysfunct
induc
advers
cardiac
remodel
heart
failur
use
human
recombin
potenti
therapi
human
heart
failur
altern
pathway
convert
ang
ang
ii
requir
ace
aceindepend
ang
ii
format
found
particularli
robust
heart
activ
eventu
assign
serin
proteinas
belong
chymas
famili
furthermor
major
cellular
sourc
chymas
mast
cell
cardiac
mast
cell
also
sourc
renin
therebi
make
critic
contribut
local
ra
heart
inde
mast
cell
play
direct
role
promot
leftventricular
dysfunct
model
congest
heart
failur
figur
summari
effect
cardiac
renal
system
transmembran
enzym
convert
ang
ang
ang
ii
ang
possess
antihypertroph
antifibrot
antiinflammatori
effect
cardiac
system
attribut
decreas
ro
product
decreas
mmp
activ
deceas
fibroblast
remodel
demonstr
antifibrot
antiapoptot
antiinflammatori
effect
along
decreas
ro
product
decreas
mesangi
matrix
expans
mmp
matrix
metalloproteinas
ro
reactiv
oxygen
speci
clinic
consequ
pathway
seen
patient
take
ace
inhibitor
chronic
incomplet
suppress
ang
ii
level
plasma
often
observ
gener
tissu
ang
ii
nonac
relat
enzym
chymas
suggest
enhanc
action
may
inde
uniqu
therapeut
role
ultim
need
better
defin
subpopul
patient
heart
failur
order
select
target
appropri
subgroup
ratio
ang
iiang
remain
elev
addit
blockad
angiotensin
ang
ii
synthesi
angiotensinconvert
enzym
ace
inhibitor
action
ang
ii
receptor
blocker
arb
increas
express
heart
given
abil
protect
advers
myocardi
remodel
increas
mediat
arb
ace
inhibit
may
part
explain
therapeut
benefit
patient
heart
failur
addit
upregul
activ
respons
mineralocorticoid
receptor
blocker
also
occur
patient
heart
failur
type
membraneanchor
protein
catalyt
activ
ectodomain
undergo
shed
due
proteolyt
action
tumor
necrosi
factor
aconvert
enzym
tace
fig
hyperact
tacemedi
cleavag
might
repres
mechan
local
ra
dysregul
occur
result
neurohumor
imbal
typic
heart
failur
inhibit
cleavag
surfac
cardiac
cell
lead
retent
enzymat
activ
reduc
ang
ii
increas
ang
within
cardiac
microenviron
may
therapeut
benefit
anim
model
comparison
cardiacspecif
versu
wholebodi
genet
knockout
complement
pharmacolog
studi
compar
supplement
genedeliv
necessari
support
hypothesi
inde
futur
develop
therapeut
agent
aid
basic
research
natur
strategi
retain
heart
would
need
account
fact
cleav
singl
site
multipl
enzym
appear
serv
sheddas
process
central
role
howev
suggest
agent
block
activ
could
effect
way
enhanc
activ
heart
kinet
evid
lend
support
idea
maintain
cardiac
ang
effect
cleav
inact
ang
ace
therefor
paracrin
signal
achiev
tether
ma
heart
might
potent
endocrin
signal
caus
system
ang
product
resolut
gene
deliveri
might
simpli
problem
dose
sinc
solubil
entir
intact
catalyt
site
share
substrat
tissuebound
would
need
dose
ang
reach
heart
achiev
similar
benefit
produc
human
recombin
administ
intraven
healthi
human
subject
random
doubleblind
placebocontrol
studi
primarili
respons
convers
ang
ii
ang
also
convert
ang
ang
singl
dose
mgkg
caus
dosedepend
increas
system
exposur
biphas
elimin
doseindepend
termin
halflif
hour
singledos
cohort
ang
ii
decreas
within
min
postinfus
either
increas
mgkg
dose
decreas
remain
unchang
mgkg
dose
wherea
angiotensin
transient
increas
dose
investig
except
lowest
dose
decreas
ang
ii
level
last
least
hour
administr
well
toler
healthi
human
subject
doseindepend
termin
elimin
halflif
rang
hour
despit
mark
chang
angiotensin
system
peptid
concentr
cardiovascular
effect
absent
suggest
presenc
effect
compensatori
mechan
healthi
volunt
multipl
line
evid
examin
ra
collect
point
express
mani
tissu
organ
system
includ
brain
retina
adipos
tissu
gastrointestin
tract
liver
heart
kidney
blood
vessel
howev
tissu
princip
interest
respect
potenti
biomark
heart
failur
heart
kidney
vascular
endothelia
analysi
activ
may
carri
tissu
plasma
sampl
analysi
plasma
sampl
less
invas
much
wide
appli
analysi
tissu
though
invas
give
specif
evid
chang
singl
system
studi
myocardium
import
analyz
rel
chang
ra
activ
within
patholog
involv
multipl
organ
system
fig
nonetheless
wide
studi
plasma
biomark
previou
work
show
reliabl
detect
human
plasma
analysi
cohort
individu
suspect
hf
plasma
activ
increas
increas
proport
confirm
hf
diagnos
also
increas
respons
worsen
diseas
statu
indic
new
york
heart
associ
function
class
investig
determin
plasma
activ
significantli
associ
leftventricular
eject
fraction
bnp
among
paramet
measur
heart
function
cohort
patient
hf
reduc
leftventricular
eject
fraction
hfref
recent
evid
patient
admit
hospit
stemi
indic
plasma
neg
correl
eject
fraction
posit
correl
infarct
size
initi
present
followup
result
analys
activ
hfref
show
strong
potenti
prognost
biomark
hf
howev
data
omit
patient
hfpef
make
signific
portion
total
heart
failur
popul
date
studi
specif
address
plasma
activ
hfpef
cohort
therefor
lack
activ
analys
focus
hfpef
identifi
critic
need
move
forward
analysi
heterogen
hfref
hfpef
well
document
imposs
suggest
gener
regard
hfref
wholli
appli
hfpef
critic
develop
activ
biomark
heart
failur
evalu
interplay
tissu
activ
plasma
activ
date
studi
concern
one
elev
plasma
activ
heart
failur
might
reflect
either
increas
shed
increas
express
perhap
combin
evid
rtpcr
analys
express
gene
upregul
human
fail
heart
disqualifi
increas
tissu
shed
anoth
mechan
plasma
activ
increas
case
heart
failur
howev
complic
issu
resolv
interplay
plasma
tissu
evid
endogen
inhibitor
exist
despit
hurdl
analys
heart
failur
thu
far
encourag
reason
continu
pursu
biomark
heart
failur
angiotensinconvert
enzym
neg
regul
ra
cleav
ang
ii
biolog
activ
ang
highli
express
heart
vasculatur
includ
endothelium
loss
enhanc
suscept
cardiovascular
diseas
includ
heart
failur
enhanc
action
prevent
advers
patholog
remodel
lessen
progress
heart
failur
thu
drug
target
use
repres
circul
detect
plasma
sampl
use
similar
fluoresc
protocol
cleavag
also
mechan
ra
dysregul
thought
occur
cardiac
patholog
potenti
candid
prevent
treat
diastol
systol
heart
failur
inde
shown
lower
plasma
ang
ii
level
healthi
human
volunt
elev
ang
ii
level
despit
ace
inhibit
occur
via
chymas
system
target
move
forward
novel
therapi
aim
enhanc
action
test
ace
inhibit
angiotensin
receptor
blocker
betablock
shown
reduc
morbid
mortal
patient
heart
failur
none
